Table 1 Patient characteristics
From: Germline genetic biomarkers to stratify patients for personalized radiation treatment
Characteristics | Group A n = 16 | Group B n = 18 | Total n = 34a |
|---|---|---|---|
n (%) | n (%) | n (%) | |
Age at diagnosis | |||
 < 65 | 10 (62.5) | 8 (44.4) | 18 (52.9) |
 ≥ 65 | 6 (37.5) | 10 (55.6) | 16 (47.1) |
Gender | |||
 Male | 15 (93.8) | 16 (88.9) | 31 (91.2) |
 Female | 1 (6.2) | 2 (11.1) | 3 (8.8) |
Smoking | |||
 ≤ 10 pack years | 11 (68.8) | 14 (77.8) | 25 (73.5) |
 > 10 pack years | 5 (31.2) | 4 (22.2) | 9 (26.5) |
T stage | |||
 0 | 1 (6.2) | 0 (0.0) | 1 (2.9) |
 1 | 3 (18.8) | 3 (16.7) | 6 (17.6) |
 2 | 5 (31.2) | 5 (27.8) | 10 (29.4) |
 3 | 4 (25.0) | 3 (16.7) | 7 (20.6) |
 4 | 3 (18.8) | 7 (38.9) | 10 (29.4) |
N stage | |||
 0 | 4 (25.0) | 3 (16.7) | 7 (20.6) |
 1 | 4 (25.0) | 3 (16.7) | 7 (20.6) |
 2 | 8 (50.0) | 6 (33.3) | 14 (41.2) |
 3 | 0 (0.0) | 6 (33.3) | 6 (17.6) |
Overall stage | |||
 I | 3 (18.8) | 2 (11.1) | 5 (14.7) |
 II | 1 (6.2) | 2 (11.1) | 3 (8.8) |
 III | 2 (12.5) | 2 (11.1) | 4 (11.8) |
 IVa | 8 (50.0) | 6 (33.3) | 14 (41.2) |
 IVb | 2 (12.5) | 6 (33.3) | 8 (23.5) |
p16 status | |||
 Positive | 5 (31.2) | 8 (44.4) | 13 (38.2) |
 Negative | 7 (43.8) | 9 (50.0) | 16 (47.1) |
 Unknown | 4 (25.0) | 1 (5.6) | 5 (14.7) |
Primary site | |||
 Oral cavity | 4 (25.0) | 6 (33.3) | 10 (29.4) |
 Oropharynx | 8 (50.0) | 7 (38.9) | 15 (44.1) |
 Larynx | 2 (12.5) | 3 (16.7) | 5 (14.7) |
 Hypopharynx | 0 (0.0) | 1 (5.6) | 1 (2.9) |
 Nasopharynx | 1 (6.2) | 0 (0.0) | 1 (2.9) |
 Nasal cavity | 0 (0.0) | 1 (5.6) | 1 (2.9) |
 Unknown | 1 (6.2) | 0 (0.0) | 1 (2.9) |
Primary treatment | |||
 Definitive | 12 (75.0) | 8 (44.4) | 20 |
 Post-operative | 4 (25.0) | 10 (55.6) | 14 |
Concurrent chemotherapy | |||
 Yes | 13 (81.2) | 14 (77.8) | 27 (79.4) |
 No | 3 (18.8) | 4 (22.2) | 7 (20.6) |